Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 1990.

https://doi.org/10.1182/blood-2019-126757

Published: 2019

Journal Articles

NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells

Alejandra Leivas, PhD BS, MSc, Laura Córdoba, MSc, Antonio Valeri, PhD, Paula Rio, PhD, Daniel Primo, PhD, Joan Ballesteros, PhD, Lucía Fernández, PhD, Antonio Perez-Martinez, MD PhD, Dean Anthony Lee, MD PhD, Daniel J. Powell, Jr., PhD, Joaquin Martinez-Lopez, MD PhD

Blood (2019) 134 (Supplement_1): 2667.

https://doi.org/10.1182/blood-2019-123371

Published: 2019

Journal Articles

Immunocytokines with Target Cell-Restricted IL-15 Activity for Induction of NK Cell Reactivity Against Acute Myeloid Leukemia (AML)

Bastian J. Schmied, MSc, Latifa Zekri, PhD, Martin Pflügler, PhD, Melanie Märklin, PhD, Lothar Kanz, Gundram Jung, Prof., MD, Helmut R. Salih, MD

Blood (2018) 132 (Supplement 1): 731.

https://doi.org/10.1182/blood-2018-99-112485

Published: 2018

Journal Articles

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Jonas Paludo, MD, Jose Villasboas Bisneto, MD, Anne J Novak, PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Esteban Braggio, PhD, Craig B. Reeder, MD, Shahrzad Jalali, PhD, Francis K. Buadi, MB, CHB, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4138.

https://doi.org/10.1182/blood-2018-99-117568

Published: 2018

Journal Articles

NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells

Alejandra Leivas, PhD BS, MSc, Paula Rio, PhD, Rebeca Mateos, MSc, Mari Liz Paciello, MD, Almudena Garcia-Ortiz, PhD, Lucia Fernandez, PhD, Antonio Perez-Martinez, MD PhD, Dean Anthony Lee, MD PhD, Daniel J. Powell, Jr., PhD, Antonio Valeri, PhD, Joaquin Martinez-Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 590.

https://doi.org/10.1182/blood-2018-99-114522

Published: 2018

Journal Articles

Activated and Expanded Natural Killer Cells Expressing an NKG2D-CAR Efficiently Target Multiple Myeloma Cells

Alejandra Leivas, PhD BS, MSc, Antonio Valeri, PhD, Paula Rio, PhD, Lucia Fernandez, PhD, Iñaki Pañero, Dean Anthony Lee, MD PhD, Daniel J. Powell, Jr., PhD, Juan Jose Lahuerta, Antonio Perez-Martinez, MD PhD, Joaquin Martinez-Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 4466.

https://doi.org/10.1182/blood.V130.Suppl_1.4466.4466

Published: 2017

Journal Articles

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359)

Janet Ayello, MS, Yaya Chu, PhD, Carolyn A. Keever-Taylor, PhD, Julie-An Talano, MD, Rona Weinberg, PhD, Mildred Semidei-Pomlaes, MS, Lee Ann Baxter-Lowe, PhD, Theodore B. Moore, MD, Sandra Fabricatore, MSN,RN, PNP, Shalini Shenoy, MD, Cori M. Abikoff, MD, Mitchell S. Cairo, MD

Blood (2016) 128 (22): 1245.

https://doi.org/10.1182/blood.V128.22.1245.1245

Published: 2016

Journal Articles

Enhancing Cytotoxicity of Autologous T Cells in AML By Blockade of CTLA-4 and PD-1

Kirsten Marie Boughan, DO, Xiaohua Chen, MD PhD, Paul Szabolcs, MD

Blood (2016) 128 (22): 4057.

https://doi.org/10.1182/blood.V128.22.4057.4057

Published: 2016

Journal Articles

High Prevalence of Functional Laa Specific Cytotoxic T Lymphocytes in Healthy Individuals-Implications for Strategies in Adoptive T Cell Therapies of Relapsed Leukemia

Sarah Matko, Marcus Odendahl, PhD, Martin Bornhaeuser, MD, Torsten Tonn, MD PhD

Blood (2015) 126 (23): 5428.

https://doi.org/10.1182/blood.V126.23.5428.5428

Published: 2015

Journal Articles

Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in-Vitro and in Humanized NSG Mice

Yaya Chu, PhD, Ashlin Yahr, Janet Ayello, MS, MT(ASCP), Mitchell S. Cairo, MD

Blood (2014) 124 (21): 1108.

https://doi.org/10.1182/blood.V124.21.1108.1108

Published: 2014

Journal Articles

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Aradhana Awasthi, PhD, Delphine C.M. Rolland, PharmD, PhD, Mona Elmacken, MD, Christopher Reggio, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damian Fermin, PhD, Matthew J. Barth, MD, Kojo S.J. Elenitoba-Johnson, MD, Megan S Lim, MD PhD, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 5481.

https://doi.org/10.1182/blood.V124.21.5481.5481

Published: 2014

Journal Articles

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Aradhana Awasthi, PhD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mona Elmacken, MD, Christopher Reggio, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 2251.

https://doi.org/10.1182/blood.V124.21.2251.2251

Published: 2014

Journal Articles

CD137 Expression Identifies Leukemia Specific CTL After In Vitro Priming Of Cord Blood T Cells

Jeyaraj Antony, PhD, Xiaohua Chen, PhD, Paul Szabolcs, MD

Blood (2013) 122 (21): 3266.

https://doi.org/10.1182/blood.V122.21.3266.3266

Published: 2013

Journal Articles

Obinutuzumab (GA101) Significantly Enhances Cell Death and ADCC Compared to Rituximab Against CD20 + sensitive and Rituximab Resistant B-Cell Non-Hodgkin Lymphoma (NHL) and Lymphoblastic Leukemia (BLL)

Aradhana Awasthi Tiwari, PhD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Danielle Glassman, Anthony Sabulski, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2012) 120 (21): 4865.

https://doi.org/10.1182/blood.V120.21.4865.4865

Published: 2012

Journal Articles

IL-15 Induced Polyclonal CTL Generated From Expanded CBT Cells Against Leukemia Cell Lines Constitutes IFN-γ Producing Cells and TCRγδ Cells

Jeyaraj Antony, PhD, Xiaohua Chen, PhD, Paul Szabolcs, MD

Blood (2012) 120 (21): 1910.

https://doi.org/10.1182/blood.V120.21.1910.1910

Published: 2012

Journal Articles

Expanded Natural Killer (NK) Cells Transfected with Anti-CD20 Chimeric Antigen Receptor (CAR) mRNA Have Significant Cytotoxicity Against Poor Risk B-Cell (CD20 + ) Leukemia/Lymphoma (B-L/L).

Yaya Chu, PhD, Janet Ayello, MS, MT(ASCP), Lowrence Lo, Jared Katz, Ashlin Yahr, Jessica Hochberg, MD, Carmella van de Ven, MA, Xianzheng Zhou, MD, PhD, Mitchell S. Cairo, MD

Blood (2012) 120 (21): 3007.

https://doi.org/10.1182/blood.V120.21.3007.3007

Published: 2012

Journal Articles

NK Cells in Hodgkin Lymphoma Are Impaired but Can Be Activated

Joerg Kessler, Katrin S. Reiners, PhD, Maike Sauer, Andreas Engert, MD, Elke Pogge von Strandmann, PhD

Blood (2011) 118 (21): 2182.

https://doi.org/10.1182/blood.V118.21.2182.2182

Published: 2011

Journal Articles

Genetically Engineered Natural Killer (NK) Cell Immunotherapy for Poor Risk B-Cell (CD20 + ) Leukemia and Lymphoma

Yaya Chu, PhD, Janet Ayello, MS, MT(ASCP), Jessica Hochberg, MD, Carmella vandeVen, MA, James Murphy, Andrew Stier, Mitchell S. Cairo, MD

Blood (2011) 118 (21): 1003.

https://doi.org/10.1182/blood.V118.21.1003.1003

Published: 2011

Journal Articles

Romedepsin (RM), a Histone Deacytelase Inhibitor (HDACi), Significantly Increases the Expression of NKG2D Ligands, MIC A/B, In Pediatric Leukemia/Lymphoma Cells (LL), Resulting In Enhanced In Vitro and In Vivo NK Cytotoxicity In NOD-SCID Mice: Translational Approach for Adoptive NK Cell Targeted Immunotherapy

Prakash Satwani, MD, Aniket Saha, MD, Sejal Bavishi, BS, Frances Zhao, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 4297.

https://doi.org/10.1182/blood.V116.21.4297.4297

Published: 2010

Journal Articles

Genetically Reengineered K562 Cells Significantly Expand Cord Blood (CB) Natural Killer (NK) Cells Ex-Vivo Expanded with Increased NK Cell Activation and Cytolytic Activity Both In-Vitro and In-Vivo: Potential Use In Adoptive Cellular Immunotherapy (ACI)

Michele Levin, MD, Janet Ayello, MS, MT(ASCP), Frances Zhao, MS, Andrew Stier, Lauren Tiffen, William Quish, Carmella vandeVen, MA, Laxmi V. Baxi, MD, Jessica Hochberg, MD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 3928.

https://doi.org/10.1182/blood.V116.21.3928.3928

Published: 2010

NARROW

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells

Immunocytokines with Target Cell-Restricted IL-15 Activity for Induction of NK Cell Reactivity Against Acute Myeloid Leukemia (AML)

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells

Activated and Expanded Natural Killer Cells Expressing an NKG2D-CAR Efficiently Target Multiple Myeloma Cells

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359)

Enhancing Cytotoxicity of Autologous T Cells in AML By Blockade of CTLA-4 and PD-1

High Prevalence of Functional Laa Specific Cytotoxic T Lymphocytes in Healthy Individuals-Implications for Strategies in Adoptive T Cell Therapies of Relapsed Leukemia

Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in-Vitro and in Humanized NSG Mice

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

CD137 Expression Identifies Leukemia Specific CTL After In Vitro Priming Of Cord Blood T Cells

Obinutuzumab (GA101) Significantly Enhances Cell Death and ADCC Compared to Rituximab Against CD20 + sensitive and Rituximab Resistant B-Cell Non-Hodgkin Lymphoma (NHL) and Lymphoblastic Leukemia (BLL)

IL-15 Induced Polyclonal CTL Generated From Expanded CBT Cells Against Leukemia Cell Lines Constitutes IFN-γ Producing Cells and TCRγδ Cells

Expanded Natural Killer (NK) Cells Transfected with Anti-CD20 Chimeric Antigen Receptor (CAR) mRNA Have Significant Cytotoxicity Against Poor Risk B-Cell (CD20 + ) Leukemia/Lymphoma (B-L/L).

NK Cells in Hodgkin Lymphoma Are Impaired but Can Be Activated

Genetically Engineered Natural Killer (NK) Cell Immunotherapy for Poor Risk B-Cell (CD20 + ) Leukemia and Lymphoma

Genetically Reengineered K562 Cells Significantly Expand Cord Blood (CB) Natural Killer (NK) Cells Ex-Vivo Expanded with Increased NK Cell Activation and Cytolytic Activity Both In-Vitro and In-Vivo: Potential Use In Adoptive Cellular Immunotherapy (ACI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only